Literature DB >> 21762457

Association of interleukin-13 C-1112T and G+2044A polymorphisms with asthma: a meta-analysis.

Haijun Yang1, Haiyan Dong, Yufei Dai, Yuxin Zheng.   

Abstract

BACKGROUND AND
OBJECTIVE: Polymorphisms in the IL13 gene have been reported to be associated with susceptibility to asthma. However, a number of studies have shown inconsistent results. A meta-analysis was performed to investigate whether polymorphisms in the IL13 gene were associated with the risk of asthma.
METHODS: Searches were performed of the Medline and Chinese National Knowledge Infrastructure (CNKI) databases, covering all papers published up to 31 August 2010. A recently proposed logistic regression-based method for meta-analysis of case-control genetic association studies was used to analyse pooled data. All statistical analyses were performed using stata version 10.0 software.
RESULTS: The IL13 C-1112T and G+2044A polymorphisms were investigated in 10 and 14 studies, respectively. The summary estimates suggested that both these polymorphisms were associated with susceptibility to asthma. Carriers of the IL13 -1112T allele had a 38.9% increased risk of asthma compared with homozygotes (-1112CC) (odds ratio (OR) 1.389, 95% confidence interval (CI): 1.103-1.749). Carriers of the IL13+2044A allele had a 40.0% increased risk of asthma compared with homozygotes (+2044GG) (OR 1.400, 95% CI: 1.137-1.724). In a subgroup analysis by ethnicity, the IL13 -1112T allele was associated with an increased risk of asthma among Caucasians (OR 1.629, 95% CI: 1.255-2.113) but not among Asians, and the IL13+2044A allele was associated with an increased risk of asthma among Asians (OR 1.436, 95% CI: 1.101-1.873) but not among Caucasians.
CONCLUSIONS: This meta-analysis indicated that the IL13 C-1112T and G+2044A polymorphisms predispose to asthma. Further studies, including pooling of individual data to facilitate evaluation of gene-gene and gene-environment interactions between these IL13 gene polymorphisms and asthma susceptibility, are recommended.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762457     DOI: 10.1111/j.1440-1843.2011.02021.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  Identification of IL13 C1923T as a Single Nucleotide Polymorphism for Asthma in Children from Mauritius.

Authors:  Kamleshun Ramphul; Li Hua; Yi Xiao Bao; Jing Yang Li; Quan Hua Liu; Ruo Xu Ji; Ding Zhu Fang
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-06-01       Impact factor: 1.349

2.  Association between the interleukin-4, interleukin-13 polymorphisms and asthma: a meta-analysis.

Authors:  Zhen-Dong Wang; Duan Lian; Jing-Ling Shen; Ruizhen Sun; Wang Xu; Zhang Xin; Lei Lei; Lian-Hong Jin; Shou-de Jin
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

3.  Effects of polymorphisms -1112C/T and +2044A/G in interleukin-13 gene on asthma risk: a meta-analysis.

Authors:  Wei Nie; Yongan Liu; Jiarong Bian; Bin Li; Qingyu Xiu
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels.

Authors:  Winnie A Okeyo; Elly O Munde; Wilson Okumu; Evans Raballah; Samuel B Anyona; John M Vulule; John M Ong'echa; Douglas J Perkins; Collins Ouma
Journal:  BMC Immunol       Date:  2013-03-25       Impact factor: 3.615

5.  Interleukin-13 +1923C/T polymorphism is associated with asthma risk: a meta-analysis.

Authors:  Yongan Liu; Tao Liu; Wei Nie; Guoxiang Lai; Qingyu Xiu
Journal:  Biomed Res Int       Date:  2013-06-11       Impact factor: 3.411

Review 6.  Interleukin-13 +2044 G/A and +1923C/T polymorphisms are associated with asthma susceptibility in Asians: A meta-analysis.

Authors:  Quanhui Mei; Jingjing Qu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.